Latest news with #PainChek
News.com.au
21-05-2025
- Business
- News.com.au
ASX medtechs chasing FDA De Novo for a shot at big US markets
Nanosonics scores FDA De Novo approval in March EMVision is also targeting De Novo for its brain scanner The company's big potential in the US When Nanosonics (ASX:NAN) landed FDA De Novo clearance for its CORIS system back in March, the market took notice, and for good reason. The CORIS system is not only a world-first device designed to clean the complex inner channels of endoscopes. It also walked the De Novo path – a route the US FDA reserves for genuinely new technologies. De Novo (which literally means "from new" in Latin) is not a simple clearance. This one is for devices without a predicate – i.e. no similar product already on the market. That means the FDA has to classify and assess the technology from the ground up. In short: it's hard to get, and a big deal if you do. Investors responded in kind, with Nanosonics' share price jumping by 13% on the news that day. Other ASX medtechs are also currently chasing De Novo clearance. PainChek (ASX:PCK), for instance, is waiting on a mid-2025 decision for its pain-assessment app. TrivarX (ASX:TRI) is also pursuing the De Novo path, with a pivotal trial in the works for its mental health wearable. Just a few years earlier, in 2016, another Aussie medtech, ProMedicus (ASX:PME), also made inroads in the States, thanks to a key partnership with none other than the prestigious Mayo Clinic. Since 2016, ProMedicus shares have gone on a jaw-dropping tear, up by more than 9000% today. Filling the CT and MRI gap Now, the $145m market capped EMvision Medical Devices (ASX:EMV) is quietly walking a similar path. We're not suggesting EMvision is about to pull a Nanosonics or do a ProMedicus victory lap. But, with De Novo ambitions of its own and an eye on cracking the US, it's probably one stock worth keeping on the radar. The Brisbane-based company is in the thick of a pivotal trial at Mayo Clinic in Florida, UTHealth in Houston, as well as the Royal Melbourne in Australia. Mayo Clinic joined the trial after clinicians there reached out to the company, having come across EMVision's EMU product. EMU is a portable, bedside brain scanner that aims to help detect strokes and bleeds where access to CT and MRI is limited or simply not practical. 'It has a physical footprint similar to a cart-based ultrasound system, and it's designed to support point-of-care diagnosis for stroke and stroke-like symptoms," EMV CEO Scott Kirkland told Stockhead. The company is also currently chasing De Novo approval for the device. But if you're wondering whether this could eventually compete with CT or MRI, the answer is… not really. And that's the point. 'We're not trying to replace a CT or an MRI. In fact, we're here to fill a gap where they are not available," said Kirkland. EMU's trials and First Responder EMU isn't just a 'me-too' device – a term for products or drugs that make minor modifications from a better known prototype. It's going after stroke, one of the biggest health problems on the planet. One in four adults will suffer a stroke in their lifetime, and most don't walk away unscathed – two out of three lead to lasting disability. What makes it worse is that many patients, especially in the regions, can't get timely access to imaging. The nearest CT could be hours away. EMU is now in a pivotal trial, aiming to enrol 300 patients across six sites; three up and running, three more to come. The primary endpoint of the trials is its ability to detect the presence or absence of haemorrhage. 'We have a gold-standard reference diagnosis expert panel that assesses all the ground truths, which are then compared with our diagnostic output to determine our sensitivity and specificity. "The minimum performance criteria is to exceed 80% sensitivity and 80% specificity. That's the minimum, but there's nothing to stop us from going as high as possible." Stroke's not the only target for EMV. One of EMVision's four trials is also focused on traumatic brain injury. Then there's the First Responder. It's backpack-sized, battery-powered, and built for use in ambulances and aeromedical units, not hospital wards. The device has already been tested with the Royal Flying Doctor Service and the Australian Stroke Alliance in outback South Australia. Next up is a trial inside a Melbourne stroke ambulance, the kind with a CT scanner in the back. 'First Responder doesn't require a specialist operator, such as a radiographer, and the output can be sent back to a neurologist to guide decision making – whether that's triage, transfer or potentially treatment at the scene," Kirkland said. Mapping the US market Crucially, EMVision isn't just taking a punt on the US, it has a clear plan for where its technology belongs. Kirkland reckons there are around 10,000 EMU opportunities across US stroke wards, ICUs and EDs. 'Within our first targets, there are really two ends of the spectrum. "One is comprehensive and primary stroke centre, the other are critical access hospitals, which are small regional clinics with 25 beds or less,' he explained. The First Responder has an even bigger runway – about 60,000 units, covering both road and air ambulances. And every scan comes with a consumable (a cap and coupling media), adding recurring revenue of around US$25 per scan for EMU, and closer to US$50 for First Responder. Kirkland is clear-eyed about what comes next. 'We've guided that we expect to head to the market kind of late calendar year 2026,' he said. 'It's a very, very large market. You can do the numbers, and if we can achieve 10% of the market, it is a very large business indeed.' With De Novo ambitions, a top-shelf US trial, and the Mayo Clinic in its corner, EMVision is playing a long game. No aggressive claims, just data collection and careful steps. But in the world of medtech, careful steps in the right direction can sometimes lead to very big leaps.
Yahoo
07-05-2025
- Business
- Yahoo
PainChek (ASX:PCK) adds AU$13m to market cap in the past 7 days, though investors from five years ago are still down 71%
It is a pleasure to report that the PainChek Limited (ASX:PCK) is up 56% in the last quarter. But that doesn't change the fact that the returns over the last half decade have been stomach churning. Five years have seen the share price descend precipitously, down a full 72%. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The fundamental business performance will ultimately determine if the turnaround can be sustained. On a more encouraging note the company has added AU$13m to its market cap in just the last 7 days, so let's see if we can determine what's driven the five-year loss for shareholders. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. PainChek isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. In the last half decade, PainChek saw its revenue increase by 50% per year. That's better than most loss-making companies. So it's not at all clear to us why the share price sunk 11% throughout that time. You'd have to assume the market is worried that profits won't come soon enough. We'd recommend carefully checking for indications of future growth - and balance sheet threats - before considering a purchase. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). ASX:PCK Earnings and Revenue Growth May 7th 2025 If you are thinking of buying or selling PainChek stock, you should check out this FREE detailed report on its balance sheet. A Different Perspective It's nice to see that PainChek shareholders have received a total shareholder return of 38% over the last year. That certainly beats the loss of about 11% per year over the last half decade. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. It's always interesting to track share price performance over the longer term. But to understand PainChek better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for PainChek (of which 1 is a bit unpleasant!) you should know about.
